Search results
Results from the WOW.Com Content Network
Depot MPA (DMPA) and EC/MPA were developed by Upjohn in the 1960s. [12] [13] DMPA (brand name Depo-Provera) was introduced for use as a progestogen-only injectable contraceptive for the first time outside of the United States in 1969 and was subsequently approved for use in birth control in the United States in 1992.
DMPA, under brand names such as Depo-Provera and Depo-SubQ Provera 104, is used in hormonal birth control as a long-lasting progestogen-only injectable contraceptive to prevent pregnancy in women. [ 38 ] [ 39 ] It is given by intramuscular or subcutaneous injection and forms a long-lasting depot , from which it is slowly released over a period ...
Hormonal therapies to reduce or stop menstrual bleeding have long been used to manage a number of gynecologic conditions including menstrual cramps (dysmenorrhea), heavy menstrual bleeding, irregular or other abnormal uterine bleeding, menstrual-related mood changes (premenstrual syndrome or premenstrual dysphoric disorder), and pelvic pain due to endometriosis or uterine fibroids.
Medroxyprogesterone acetate (brand names Depo-Provera, Provera, Depo-subQ Provera 104) [4] – 150 mg (intramuscularly) or 104 mg (subcutaneously) every 3 months [3] Norethisterone enanthate (brand names NET EN, Noristerat, Norigest, Doryxas) [ 5 ] – 200 mg (intramuscularly) every 2 months [ 3 ]
Premenstrual water retention could be passed off as little weight gain before the start of a menstruation cycle, but should be carefully watched if weight is gained quickly within days. Water retention can cause serious consequences in people who have a kidney or cardiovascular disease and should take extra caution when experiencing this symptom.
Risk of VTE with estrogen and progestogen therapy is highest at the start of treatment, particularly during the first year, and decreases over time. [ 89 ] [ 123 ] Older age , higher body weight , lower physical activity , and smoking are all associated with a higher risk of VTE with oral estrogen and progestogen therapy.
In this Dec. 23, 1973, file photo, cars line up in two directions at a gas station in New York City. Right-on-red was a gas-savings tool during the 1970s oil crisis.
Due to its long half-life, zuclomifene can be detected in urine for at least 261 days after discontinuation [24] (261 days after discontinuation with a half-life of 30 days, there is still 0.24% of the peak level of zuclomifene being excreted, whereas with a half-life of ten hours, enclomifene reaches the same 0.24% level in less than four days ...